These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 476624)
1. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule. Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer. Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775 [TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule. Woodcock TM; Schneider RJ; Young CW Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma. Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer. Tan CT; Hancock CH; Mondora A; Hoffman NW Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381 [TBL] [Abstract][Full Text] [Related]
8. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)]. Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929 [TBL] [Abstract][Full Text] [Related]
10. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. Stanton GF; Raymond V; Wittes RE; Schulman P; Budman D; Baratz R; Williams L; Petroni GR; Geller NL; Hancock C Cancer Res; 1985 Apr; 45(4):1862-8. PubMed ID: 3978646 [TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631 [TBL] [Abstract][Full Text] [Related]
12. Phase I-II study of m-AMSA administered as a continuous infusion. Micetich KC; Zwelling LA; Gormley P; Young RC Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma. Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573 [TBL] [Abstract][Full Text] [Related]
14. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer. Currie VE; Howard J; Wittes R Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189 [TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of dihydroxyanthracenedione. Van Echo DA; Whitacre MY; Aisner J; Wiernik PH Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015 [TBL] [Abstract][Full Text] [Related]
17. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma. Warrell RP; Straus DJ; Young CW Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952 [TBL] [Abstract][Full Text] [Related]
18. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer. Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657 [TBL] [Abstract][Full Text] [Related]
19. The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Cysyk RL; Shoemaker D; Adamson RH Drug Metab Dispos; 1977; 5(6):579-90. PubMed ID: 21782 [TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]